ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the 'Class Period'), of the important August 25, 2025 lead plaintiff deadline.
SO WHAT: If you purchased Sarepta securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Sarepta class action, go to https://rosenlegal.com/submit-form/?case_id=20094 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (3) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (4) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Sarepta class action, go to https://rosenlegal.com/submit-form/?case_id=20094 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
——————————-
Contact Information:
Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Lucid (LCID) Shares Skyrocket, What You Need To Know
What Happened? Shares of luxury electric car manufacturer Lucid (NASDAQ:LCID) jumped 7.3% in the afternoon session after the company announced that all of its Air models will gain access to Tesla's Supercharger network and revealed enhancements for its 2026 vehicle lineup. Starting July 31, 2025, all Lucid Air owners will be able to use Tesla's expansive North American Supercharger network with an approved adapter, a move that significantly broadens charging options and could alleviate range anxiety for customers. In addition to this expanded charging access, Lucid announced updates for its 2026 models. The company increased the EPA-estimated range for the Lucid Air Touring model by over 6% to 431 miles and added new standard equipment across the lineup, including an improved air conditioning compressor for better cooling and reduced noise. These enhancements signaled the company's focus on improving customer experience and maintaining its competitive edge in the luxury EV market. Is now the time to buy Lucid? Access our full analysis report here, it's free. What Is The Market Telling Us Lucid's shares are extremely volatile and have had 56 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 5 days ago when the stock gained 39% on the news that the company announced a major partnership with Uber (NYSE: UBER) and autonomous vehicle company Nuro to launch a global, premium robotaxi program. The collaboration will integrate Lucid's electric vehicles with Nuro's Level 4 autonomous driving system, making them available exclusively on Uber's ride-hailing platform. The ambitious plan aims to deploy 20,000 or more of these autonomous Lucid vehicles over the next six years, with the first launch expected in a major U.S. city next year. This strategic alliance is a significant vote of confidence in Lucid's vehicle technology. As part of the deal, Uber plans to make multi-hundred-million dollar investments in both Lucid and Nuro. For Lucid, this partnership opens up a substantial new revenue stream and a direct path into the burgeoning autonomous ride-sharing market, leveraging Uber's massive global network. The deal combines Lucid's vehicle design, Nuro's self-driving tech, and Uber's fleet management to create a purpose-built robotaxi experience. Lucid is up 1.3% since the beginning of the year, but at $3.07 per share, it is still trading 27.9% below its 52-week high of $4.26 from August 2024. Investors who bought $1,000 worth of Lucid's shares at the IPO in September 2020 would now be looking at an investment worth $310.41. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Boston Globe
42 minutes ago
- Boston Globe
As the dollar slides, the Euro is picking up speed
'We are witnessing a profound shift in the global order: Open markets and multilateral rules are fracturing, and even the dominant role of the U.S. dollar, the cornerstone of the system, is no longer certain,' she wrote last month. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The dollar's role as the world's reserve currency gives the United States an 'exorbitant privilege' — a term coined begrudgingly by a French politician in the 1960s. Because investors, governments and central banks around the world seek the safe, predictable returns of dollar-denominated assets such as Treasury bonds, there is a robust, built-in demand for dollars. That makes it easier for the U.S. government to borrow and boosts the spending power of American consumers. Advertisement The eurozone, which is made up of the 20 countries that use the euro and rivals the United States in terms of size and wealth, has never attracted investors in the same way. The euro ranks a distant second to the dollar in global use. Advertisement The euro's recent rise is a major reversal from just three years ago, when it dropped to parity with the dollar because investors feared the damage of surging inflation and Russia's invasion of Ukraine. And it is a world away from the eurozone debt crisis last decade, when at times the currency union seemed at risk of crumbling. As welcome as the euro's recovery from those episodes has been — the euro is trading near a record high against the currencies of dozens of major trading partners — it is also possible to have too much of a good thing. As money flows into the euro and euro-denominated assets such as German government bonds, economists and executives warn that the currency's strength could hurt exporters. They are already contending with Trump's tariffs, which make their goods more expensive for buyers abroad, as well as increased competition from Chinese rivals in key markets. 'Further euro strength is likely to be self-defeating,' said Valentin Marinov, a currency strategist at Crédit Agricole, a French bank. Exports were already likely to weaken and become a drag on the eurozone economy because of U.S. tariffs and European government policies that would encourage more imports. After a surge in energy prices led to years of fighting to bring inflation down, the European Central Bank, which sets interest rates for the eurozone, now faces the prospect that inflation could be too low. The bank forecasts inflation to average 1.6% next year, notably below its 2% target. That's partly because of the impact of a strong euro, which makes imports cheaper. Advertisement Some policymakers have said there is a risk that sluggish inflation will become entrenched, which is a familiar problem for the region. For nearly a decade until 2021, the central bank kept its key interest rates below zero in hopes of spurring faster economic growth and encouraging prices to rise steadily. That, policymakers hoped, would feed through to higher wage growth and better living standards. ECB officials are expected to keep interest rates steady when they meet this week, but analysts are adding to bets they could cut rates again later this year, if the economic outlook darkens or the euro's strength pushes inflation forecasts even lower. Reducing interest rates tends to weaken a currency, but the euro's recent strength has come, notably, as the ECB cut rates eight times in a year. Luis de Guindos, the vice president of the central bank, said that if the euro climbed above $1.20, that 'would be much more complicated.' Some big European companies have warned about the effect of the strong currency on their earnings, especially in export-heavy Germany. SAP, a software firm that recently became Europe's most valuable public company, said every 1-cent increase in the euro-dollar exchange rate results in a 30 million euro decline in revenues, without currency hedges. Adidas, the sportswear brand, said a strong euro had 'negative translation effects' on its overseas sales. Daimler, a truck maker, said fluctuations in the euro-dollar rate 'could significantly impact' its financial performance. Where the euro goes next is hard to predict. Analysts surveyed by Bloomberg expect the euro to continue strengthening, to $1.21 next year. But Marinov said he believed that traders had gotten ahead of themselves: He expects the euro to fall back toward $1.10 next year. Advertisement The currency's rally this year does not necessarily mean there will be a lasting shift toward the euro, in which it accounts for a larger share of central banks' reserves or is used in more cross-border payments. Lagarde said seizing the moment for a 'global euro' would take a concerted effort to bolster the bloc's fragmented economy, streamline its governance and deepen its capital markets, among other things. 'A step towards greater international prominence for our currency will not happen by default: It must be earned,' she said. This article originally appeared in .
Business Wire
an hour ago
- Business Wire
Invisalign® Palatal Expander System by Align Technology Now Available in Malaysia for Skeletal and Dental Expansion in Growing Patients
KUALA LUMPUR, Malaysia--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Align's Invisalign Palatal Expander System* has been notified as Class B medical device by Malaysia Medical Device Authority and is now commercially available in Malaysia for broad patient applicability, including growing children, teens and adults (with surgery or other techniques). The Invisalign Palatal Expander System* is a modern and innovative direct 3D printed device based on proprietary and patented technology. Invisalign Palatal Expanders are intended for use in rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed, or permanent dentition during treatment of patients. 'The Invisalign Palatal Expander System* exemplifies our commitment to advancing digital orthodontics with innovative solutions that enhance patient treatment experiences,' said David Carr, Align Technology executive vice president and managing director, Asia Pacific. 'We are excited to extend the availability of the transformative Invisalign Palatal Expander system, Align's first direct 3D printed orthodontic appliance, to even more doctors and their patients markets across the Asia Pacific region.' The Invisalign Palatal Expander System* consists of a series of removable devices staged in small increments of movement to expand a patient's narrow maxilla to a position determined by their treating doctor. Each direct 3D printed device is customized to the patient's unique anatomy based on an iTero™ intraoral digital scan. A palatal expansion treatment plan and device design are then developed using Align's proprietary AI-driven orthodontic software. Combined with Invisalign First™ aligners, Invisalign Palatal Expanders provide doctors with a full early intervention treatment solution for Phase 1 treatment, an early interceptive orthodontic treatment for young patients. Phase 1 treatment is traditionally done through arch expanders or partial metal braces, before all permanent teeth have erupted – typically at ages 6 through 10. Invisalign First clear aligners are designed specifically to address a broad range of younger patients' malocclusions, including shorter clinical crowns, management of erupting dentition, and predictable dental arch expansion. 'Phase 1 or early interceptive treatment accounts for 20 percent of orthodontic case starts each year and is growing,' said Dr. Mitra Derakhshan, Align Technology executive vice president, chief clinical officer, global treatment planning and clinical services. 'Together with Invisalign First aligners, Invisalign Palatal Expanders provide doctors with a solution set to treat the most common skeletal and dental malocclusions in growing children. The addition of mandibular advancement features to Invisalign aligners also provides doctors with more options for treating skeletal and dental jaw imbalances and bite correction for their growing patients during their teenage years.' The Invisalign Palatal Expander System* is available in Australia, New Zealand, Hong Kong, Singapore, Vietnam, Japan, Thailand, India and Malaysia. * Children shall not use device without supervision. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign® System, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and is key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat approximately 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align Digital Platform™, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, and Align Digital Platform are trademarks of Align Technology, Inc. About the Invisalign Palatal Expander System The Invisalign Palatal Expander System is a modern, innovative direct 3D printed orthodontic appliance designed based on proprietary and patented technology. The Invisalign Palatal Expander System is intended for the orthodontic treatment of malocclusion. The system is used for the rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw, dental arch and teeth, palate) with primary, mixed, or permanent dentition during orthopedic treatment in children or adolescents. In adults, it is to be used in conjunction with surgery or other interventions when necessary. Devices are 3D printed and are manufactured based on digital scan data from commercially available iTero™ intraoral scanners offered by Align Technology, Ltd. The devices are removable for proper oral hygiene; manufactured to custom fit each patient's anatomy for optimal comfort and aesthetics, expanders fit comfortably in the patient's mouth and are changed daily (no screw required). The System is comprised of Invisalign Palatal Expanders (active expansion, each stage comes with a programmed expansion of up to 0.25mm/stage, changed daily or as per doctor's discretion) and Invisalign Palatal Holders (copies of the last stage of the expansion phase designed to hold the maxilla post-active expansion and changed every 2-4 weeks as directed by the treating doctor), Invisalign Attachment Templates and proprietary 3D shape generation software. These products are not available for purchase by the general public. However, the products are available for purchase from Invisalign® trained dentists and orthodontists.
